ArticleNature communications2022
Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial.The Journal of antimicrobial chemotherapy · 2024Trial
- Using hyperpolarised xenon magnetic resonance imaging to explore breathlessness in long COVID: results from the EXPLAIN study.ERJ open research · 2026Article
- Quantitative analysis of massive SARS-CoV-2 testing in the community in France in 2021-2022 reveals the associations of variant, vaccination, and age with viral dynamics in symptomatic individuals.PLoS computational biology · 2026Article
- Global disparities in the introduction, scale-up, and effectiveness evaluation of COVID-19 vaccines.Nature communications · 2025Article
- The Association between COVID-19 Status and Economic Costs in the Early Stages of the COVID-19 Pandemic: Evidence from a UK Symptom Surveillance Digital Survey.PharmacoEconomics - open · 2025Article
- Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis.Frontiers in immunology · 2025Article
- Mortality involving and not involving COVID-19 among vaccinated vs. unvaccinated in England between Apr 21 and May 23.F1000Research · 2025Article
- A national population-based study of mortality and risk factors in COVID-19-hospitalized patients in Spain (2020-2021).Frontiers in public health · 2025Article
- The Impact of Vaccination on COVID-19 Outcomes in Vietnam.Diagnostics (Basel, Switzerland) · 2024Article
- The Impact of Healthcare Pressures on the COVID-19 Hospitalisation Fatality Risk in England.Journal of epidemiology and global health · 2024Observational
- The effectiveness of COVID-19 vaccination in preventing hospitalisation and mortality: A nationwide cross-sectional study in Iran.Journal of global health · 2024Article
- Telemedical management of symptomatic COVID-19 outpatients.ERJ open research · 2024Article
- Effects of antivirals on patients with COVID-19 breakthrough.BMC infectious diseases · 2024Article
- Nosocomial SARS-CoV-2 Infections and Mortality During Unique COVID-19 Epidemic Waves.JAMA network open · 2023Article
- Investigation of Initial Viral Loads and Patient Characteristics as Predictors of COVID-19 Outcomes: A Retrospective Cohort Study.Infectious disease reports · 2023Article
- The influence of sociodemographic factors on COVID-19 vaccine certificate acceptance: A cross-sectional study.Human vaccines & immunotherapeutics · 2023Article
- Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.BMC medicine · 2023Article
- Peculiar weather patterns effects on air pollution and COVID-19 spread in Tokyo metropolis.Environmental research · 2023Observational
- Long-term exposure to air pollution and COVID-19 severity: A cohort study in Greater Manchester, United Kingdom.Environmental pollution (Barking, Essex : 1987) · 2023Article
- Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Widespread vaccination campaigns have changed the landscape for COVID-19, vastly altering symptoms and reducing morbidity and mortality. We estimate trends in mortality by month of admission and vaccination status among those hospitalised with COVID-19 in England between March 2020 to September 2021, controlling for demographic factors and hospital load. Among 259,727 hospitalised COVID-19 cases, 51,948 (20.0%) experienced mortality in hospital. Hospitalised fatality risk ranged from 40.3% (95% confidence interval 39.4-41.3%) in March 2020 to 8.1% (7.2-9.0%) in June 2021. Older individuals and those with multiple co-morbidities were more likely to die or else experienced longer stays prior to discharge. Compared to unvaccinated people, the hazard of hospitalised mortality was 0.71 (0.67-0.77) with a first vaccine dose, and 0.56 (0.52-0.61) with a second vaccine dose. Compared to hospital load at 0-20% of the busiest week, the hazard of hospitalised mortality during periods of peak load (90-100%), was 1.23 (1.12-1.34). The prognosis for people hospitalised with COVID-19 in England has varied substantially throughout the pandemic and according to case-mix, vaccination, and hospital load. Our estimates provide an indication for demands on hospital resources, and the relationship between hospital burden and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.